CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 50.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,800 shares of the company's stock after purchasing an additional 28,400 shares during the quarter. Two Sigma Advisers LP owned 0.10% of CRISPR Therapeutics worth $3,338,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Western Pacific Wealth Management LP increased its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Spire Wealth Management grew its stake in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after acquiring an additional 1,482 shares during the last quarter. First Horizon Advisors Inc. raised its position in CRISPR Therapeutics by 33.4% during the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock worth $80,000 after acquiring an additional 511 shares during the last quarter. Elkhorn Partners Limited Partnership raised its position in CRISPR Therapeutics by 22.6% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company's stock worth $150,000 after acquiring an additional 700 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its position in CRISPR Therapeutics by 34.2% during the fourth quarter. Farther Finance Advisors LLC now owns 3,834 shares of the company's stock worth $151,000 after acquiring an additional 977 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,953 shares of company stock valued at $736,087 over the last ninety days. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Price Performance

CRSP stock traded down $0.74 during midday trading on Friday, reaching $36.04. 2,078,440 shares of the company's stock traded hands, compared to its average volume of 1,709,615. The company has a market capitalization of $3.11 billion, a P/E ratio of -8.25 and a beta of 1.88. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The business has a 50-day moving average price of $36.59 and a two-hundred day moving average price of $41.43.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.43) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of research reports. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Citigroup lowered their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. Finally, Barclays lowered their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.